



Form PTO-1449				Docket Number 47508.528	Application Number 09/845,623
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Agrawal	
				Filing Date April 30, 2001	Group Art Unit
Sheet	1	OF	1		

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,149,798	09/22/92	Agrawal et al.	536	27	

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
	A1	Khorana et al. (1972) "Studies on Polynucleotides," <i>J. Molec. Biol.</i> 72:209
	A2	Reese (1978) "The Chemical Synthesis of Oligo- and Poly-Nucleotides By The Phosphotriester Approach," <i>Tetrahedron</i> 34:3143-3179
	A3	Beaucage et al. (1981) "Deoxynucleoside Phosphoramidites - A New Class of Key Intermediates for Deoxypolynucleotide Synthesis," <i>Tetrahedron Lett.</i> 22:1859-1862
	A4	Connolly et al. (1984) "Synthesis and Characterization of an Octanucleotide Containing the EcoRI Recognition Sequence With A Phosphorothioate Group At The Cleavage Site," <i>Biochemistry</i> 23:3443
	A5	Agrawal et al. (1987) "Oligodeoxynucleotide Methylphosphonates: Synthesis and Enzymic Degradation," <i>Tetrahedron Lett.</i> 28(31):3539-3542
	A6	Jager et al. (1988) Oligonucleotide N-Alkylphosphoramidates: Synthesis and Binding to Polynucleotides," <i>Biochemistry</i> 27:7237
	A7	Agrawal et al. (1988) "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates As Inhibitors of Human Immunodeficiency Virus," <i>Proc. Natl. Acad. Sci. USA</i> 85:7079-7083
	A8	Zon et al. (1991) "Phosphorothioate Oligonucleotides" <i>Oligonucleotides and Analogues: A Practical Approach</i> pp. 87-108
	A9	Agrawal (1992) "Antisense Oligonucleotides as Antiviral Agents," <i>Trends in Biotechnology</i> 10:152-158
	A10	Kuramoto et al. (1992) "Oligonucleotide Sequences Required For Natural Killer Cell Activation," <i>Jpn. J. Cancer Res.</i> 83:1128-1131
	A11	Zon (1993) "Protocols for Oligonucleotides and Analogs," <i>Methods in Molecular Biology</i> Vol. 20, pp. 165-189
	A12	Crooke (ed) (1993) Antisense Research and Applications CRC Press, Boca Raton, Florida
	A13	McIntyre et al. (1993) "A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-kB p65 Causes Sequence-Specific Immune Stimulation," <i>Antisense Res. Dev.</i> 3:309-322
	A14	Agrawal et al. (1995) "Modified Oligonucleotides as Therapeutic and Diagnostic Agents," <i>Curr. Opin. Biotechnol.</i> 6:12-19
	A15	Crooke (1998) "An Overview of Progress in Antisense Therapeutics," <i>Antisense Nucleic Acid Drug Dev.</i> 8:115-122
	A16	Krieg et al. (1995) "CpG Motifs In Bacterial DNA Trigger Direct B-Cell Activation," <i>Nature</i> 371:546-549
	A17	Liang et al. (1996) "Activation of Human B Cells By Phosphorothioate Oligodeoxynucleotides," <i>J. Clin. Invest.</i> 98:1119-1129
	A18	McCluskie et al. (1998) "Cutting Edge: CpG DNA Is A Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice," <i>J. Immunol.</i> 161:4463-4466
	A19	Moldoveanu et al. (1998) "CpG DNA, A Novel Immune Enhancer for Systemic and Mucosal Immunization With Influenza Virus," <i>Vaccine</i> 16:1216-1224
	A20	Agrawal et al. (2000) "Antisense Therapeutics: Is It As Simple As Complementary Base Recognition?" <i>Mol. Med. Today</i> 6:72-81
EXAMINER DATE CONSIDERED 12/19/02		
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.		

Subt. For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
HYB-004US2Application Number
09/845,623Applicant
Agrawal et al.Filing Date
April 30, 2001Group Art Unit
1623

Sheet

1

OF

1

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/49288	11/1998	PCT				X
	WO 01/12804 A2	02/2001	PCT				X

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

	A1	Zhao, Q. et al., <i>Bioorganic & Medicinal Chemistry</i> , "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligonucleotide Modulates Its Immunostimulatory Activity", pp. 3453-3458, 1999.
	A2	Moldoveanu, Z. et al., <i>Vaccine</i> , "CpG DNA, a Novel Immune Enhancer for Systematic and Mucosal Immunization With Influenza Virus", 16:1216-1224, 1998.
	A3	Krieg, Arthur M., <i>Applied Antisense Oligonucleotide Technology</i> , "Leukocyte Stimulation By Oligodeoxynucleotides", pp. 431-448, 1998.
	A4	Kandimalla, E.R. et al., <i>Bioorganic & Medicinal Chemistry</i> , "Effect of Chemical Modifications of Cytosine and Guanine in a CpG-Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships", pp. 807-813, 2001.
	A5	Ekambar, D.Y. et al., <i>Bioorganic & Medicinal Chemistry</i> , "Modulation of Immunostimulatory Activity of CpG Oligonucleotides by Site-Specific Deletion of Nucleobases", pp. 2263-2267, 2001.
	A6	
	A7	
	A8	
	A9	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not conformance and not considered. Include copy with next communication to applicant.

Bos 1216555v2